Zai Lab stock reports USD 106.31 million in Q2 revenue
Published on 09/24/2026 at 10:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Zai Lab stock stood at USD 26.44 on NASDAQ at the September 23, 2026 close, while second-quarter revenue reached USD 106.31 million. The biotechnology company delivered an ADS loss of USD 0.46 against a USD 0.68 consensus loss, a USD 0.22 improvement versus expectations.
Revenue falls to USD 106.31 million
The Globe and Mail reported that total revenue in Q2 2026 was USD 106.3 million, compared with USD 110.0 million in Q2 2025. That represents a 3.36 percent year-over-year decline, while the company posted a net loss of USD 50.8 million for the quarter ended June 30, 2026.
The product business offered a more constructive comparison. Net product revenue rose 11 percent from the prior quarter to USD 105.8 million, supported by stabilization at ZEJULA and volume growth for VYVGART. The contrast suggests that product execution, rather than total reported revenue alone, is the key near-term measure.
Analysts see USD 37.25 target
As MarketBeat reported on September 23, 2026, seven analysts carried a Moderate Buy consensus and an average 12-month price target of USD 37.25. The target stands USD 10.81 above the September 23 price, equivalent to 40.87 percent.
The same analyst snapshot listed four buy ratings, one strong buy, one hold and one sell. That distribution places the emphasis on execution: the commercial portfolio must offset the revenue pressure shown by the 3.36 percent year-over-year decline.
2027 growth is the next checkpoint
Management expects meaningful year-over-year growth in 2027, with KarXT identified as a key driver and the internal pipeline expected to contribute more to revenue and margins beyond 2027. The company also anticipates a first US product launch in 2028, according to the Q2 2026 earnings transcript.
For investors, the immediate read-through is the gap between the 11 percent sequential product-revenue increase and the 3.36 percent annual total-revenue decline. That spread defines the transition from stabilization to renewed growth.
Stock remains below yearly high
Zai Lab stock closed at USD 26.44 on NASDAQ on September 23, 2026, up USD 0.03, or 0.11 percent, from the prior close. Its 52-week range was USD 15.96 to USD 34.72, leaving the stock 23.85 percent below the yearly high.
Zai Lab stock key facts
- Company: Zai Lab Limited
- Ticker: ZLAB
- Trading venue: NASDAQ
- Price (September 23, 2026): USD 26.44 closing price
- Market capitalization: USD 2,985,671,799 as of September 23, 2026
- 52-week range: USD 15.96-34.72
- Sector / Industry: Healthcare / Biotechnology
